gip/glp-1 receptor agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight Understand GLP-1/GIP Dual Agonist Tirzepatide

Consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia

The comparison between phentermine and GLP-1 medications and the phentermine versus semaglutide comparison may also be relevant for patients exploring lower-cost pharmaceutical alternatives when GLP-1 access becomes restricted

By 2024, an estimated 12% of American adults reported taking a GLP-1 medication for diabetes, weight loss, or heart disease, according to data from the Kaiser Family Foundation

The convenience differential between weekly injectables and daily oral formulations creates distinct patient preference segments: some patients prioritize dosing frequency, others prefer avoiding injections entirely

The GLP-1 Analogue Lixisenatide Decreases Atherosclerosis in Insulin-Resistant Mice by Modulating Macrophage Phenotype

Cardiovascular safety of antidiabetic medications has received increasing attention since 2008 and here we summarize the recent updates from both clinical trials and preclinical experiments on the cardiovascular outcomes of this class of glucose-lowering drugs